The Conversation (0)
Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company.
"Brian is joining our Board during a pivotal phase, as we transition to becoming a fully integrated biotechnology company poised to commercialize our first potential product in 2027," said Jason Rhodes, chairman of Dyne's Board of Directors and partner at Atlas Venture. "With a perspective shaped by deep experience in the capital markets, Brian brings a keen focus on disciplined growth and value creation, and we welcome his insights and leadership."
"I am honored to join Dyne's Board of Directors at this exciting time," said Brian Posner. "Dyne's mission to deliver meaningful functional improvement for people with neuromuscular diseases resonates with me, and I look forward to partnering with the team as it advances near-term clinical data in support of upcoming regulatory milestones while delivering sustainable shareholder value."
"Brian is a highly respected leader whose expertise in investment stewardship, executive leadership and governance will further strengthen our Board," said John Cox, president and chief executive officer (CEO) of Dyne. "His appointment underscores our commitment to building the world's leading neuromuscular disease company and advancing meaningful new therapeutics for patients in need."
Mr. Posner is founder and president of Point Rider Group (UK) Ltd, an advisory and consulting firm that provides independent strategic counsel to senior executives, boards of directors and institutional investors. Previously, he served as president and CEO of ClearBridge Advisors, a $100 billion+ asset management firm, and as partner and managing director at Warburg Pincus, following earlier senior investment roles at Hygrove Partners and Fidelity Investments.
An experienced board leader, Mr. Posner currently serves as a director of Arch Capital Group (ACGL) and has previously chaired the AQR Funds and Bioverativ (BIVV), and served as a director of Biogen (BIIB), Sotheby's (BID) and The Mutual Fund Store. Beyond his corporate roles, he is a Life Trustee of Northwestern University, serves on the Advisory Board of its Center for the Study of Diversity and Democracy, and holds degrees from Northwestern University (BA) and the University of Chicago Booth School of Business (MBA).
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook .
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne's strategy, future operations, prospects and plans, objectives of management, the potential commercialization of Dyne's first product in 2027, the timing and outcome of clinical data releases and regulatory interactions, and the potential to deliver shareholder value, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "predict," "project," "potential," "should," "will" or "would," or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne's ability to enroll patients in clinical trials; whether results from preclinical studies and initial data from early clinical trials will be predictive of the final results of the clinical trials or future trials; uncertainties as to the FDA's and other regulatory authorities' interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and the regulatory approval process; whether Dyne's cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne's filings with the Securities and Exchange Commission (SEC), including the Company's most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne's views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne's views as of any date subsequent to the date of this press release.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
